Modified GRF (1-29) is a synthetic analogue of sermorelin [GHRH(1-29)-NH2] with four substitutions (D-Ala2, Gln8, Ala15, Leu27). Unlike CJC-1295, it lacks the drug affinity complex (DAC), a C-terminal maleimidopropionyl-lysine extension. It has been studied in cell and animal models of growth hormone release, and the literature sometimes confuses the names CJC-1295 and Modified GRF (1-29).
Class
GHRH (1-29) analogue
Type
peptide, 29 residues
Also known as
Modified GRF (1-29), Mod GRF 1-29, CJC-1295 without DAC
Sequence
Y-(D-Ala)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2
Molecular formula
C152H252N44O42
Molecular weight
3367.9 g/mol
Regulatory status
Not an approved medicine. The related CJC-1295 (with DAC) reached phase II trials before development was stopped, and FDA listed CJC-1295 as a compounding substance with safety concerns (nomination later withdrawn).
This sheet describes a molecule and the published research on it. It is not advice about use, and SHLabz products are not for human or veterinary use.
Trusted research supplier — UAE & GCC
The UAE & GCC’s Trusted Source for Lab‑Verified Research Peptides
Research-grade peptides at ≥99% purity, third-party HPLC tested and
released against a certificate of analysis. 1–2 working days across the UAE, 3–5 across the GCC.
≥99% purity, third-party HPLC tested and
released against a certificate of analysis. Dispatched the same working day.
